Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein and Special Advisor Larry Latowski joined Steve Darling from Proactive Vancouver with news the company has signed their first contract for their slow release tablets with MediPharm.
Goldstein discusses how the deal with work and what is it worth to the company. Meanwhile, Latowski discusses why he is joining the company and what he sees as the big advantages Canntab has over others.
CSE:PILL
Market: CSE
Market Cap: $33.04 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Full interview: Canntab Therapeutics raised 3 million dollars and receives...
Canntab Therapeutics (CSE: PILL-OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive in Vancouver to discuss the major announcement from the company that they have received their key Heath Canada Licence that allows them Processing & Sales for Medical...
on 03/03/2020
2 min read
Prev article
3 min read
